Xenograft and organoid model systems in cancer research.

Bleijs M, van de Wetering M, Clevers H, Drost J. · 2019

Read Xenograft and organoid model systems in cancer research. by Bleijs M, van de Wetering M, Clevers H, Drost J. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6670015.txt.

Introduction

Bleijs and co-authors compare patient-derived xenografts and tumour organoids as cancer models. Their review appears in The EMBO Journal. Both systems preserve features of the parent tumour. Genetic and phenotypic heterogeneity survive in each. Organoids grow straight from primary patient material. They establish and expand with high efficiency. Xenografts need host animals instead. In return they keep tumour-stroma interactions intact. Those interactions feed tumorigenesis in patients.

The review traces recent advances in both systems. Applications span drug testing and resistance studies. Promises and challenges are weighed side by side. Neither model wins on every front. The authors guide readers on matching model to question.

Catalog record

CREATORBleijs M, van de Wetering M, Clevers H, Drost J.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE63 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6670015

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Xenograft and organoid model systems in cancer research By Margit Bleijs, Marc van de Wetering, Hans Clevers, Jarno Drost Published in: The EMBO Journal DOI: 10.15252/embj.2019101654 ABSTRACT Abstract Patient‐derived tumour xenografts and tumour organoids have become important preclinical model systems for cancer research. Both models maintain key features from their parental tumours, such as genetic and phenotypic heterogeneity, which allows them to be used for a wide spectrum of applications. In contrast to patient‐derived xenografts, organoids can be established and expanded with high efficiency from primary patient material. On the other hand, xenografts retain tumour–stroma interactions, which are known to contribute to tumorigenesis. In this review, we discuss recent advances in patient‐derived tumour xenograft and tumour organoid model systems and compare their promises and challenges as preclinical models in cancer research. Keywords: cancer, organoids, preclinical models, tumour heterogeneity, xenografts Subject Categories: Cancer, Molecular Biology of Disease, Synthetic Biology & Biotechnology INTRODUCTION Cancers consist of a continuously evolving heterogeneous cell mass (McGranahan & Swanton, 2017). Importantly, not all cells within a tumour contribute equally to its progression. Early studies on mouse mammary tumours revealed that cellular subpopulations from different regions of the same tumour vary in growth rate, drug response, immunogenicity and metastatic capacity (reviewed in Heppner, 1984; Tabassum & Polyak, 2015). This intra‐tumour heterogeneity can arise from both genetic and non‐genetic variability within tumours, such as variations in availability of resources, like differential access to oxygen and nutrients (Kreso & Dick, 2014; Tabassum & Polyak, 2015). The development of preclinical model systems phenocopying tumour heterogeneity is required for studying its contribution to tumour progression and acquisition of therapy resistance. Whereas the first patient‐derived tumour xenograft (PDTX) models were successfully established during the fifties (Toolan, 1953), patient‐derived tumour organoid (PDTO) models have been established only during the last decade (Sato et al, 2011) (Fig 1). Both PDTX and PDTO model systems are able to recapitulate the intra‐ and inter‐tumour heterogeneity seen in human cancers (Beckhove et al, 2003; Guenot et al, 2006; Huang et al, 2015; van de Wetering et al, 2015; Bruna et al, 2016; George et al, 2017; Nanki et al, 2018; Sachs et al, 2018; Yan et al, 2018). Therefore, these models are promising tools to study sub‐clonal dynamics within individual tumours during progression and therapy resistance (Shi et al, 2014). [Figure: Timeline PDTX and PDTO development(Toolan, 1953; Taetle et al, 1987; Fu et al, 1992; Beckhove et al, 2003; Fichtner et al, 2004; Shultz et al, 2005; Wang et al, 2005; Cutz et al, 2006; Sato et al, 2009, 2011; Hennessey et al, 2011; Gao et al, 2014; Karthaus et al, 2014; Boj et al, 2015; Lee et al, 2018; Li et al, 2018, 2019; Sachs et al, 2018; Yan et al, 2018; Kopper et al, 2019; Schutgens et al, 2019).] Due to the complexity of human tumours, response to clinical cancer treatments varies substantially. Additionally, mechanisms of tumour progression are poorly defined as well as drug efficacy and resistance. While a high number of anti‐cancer compounds tested for clinical safety in Phase I studies progress to Phase II efficacy testing, most of these compounds fail in Phase II and III studies, which examine the power of pharmacological responses (Dimasi et al, 2013). Such high failure rates in clinical trials headline the need of preclinical efficacy models for improved predictions of clinical outcome. Several human preclinical models are currently used, including cancer cell lines, PDTX and PDTO cultures (Figs 1 and 2). These models have improved our understanding of the mechanisms of cancer progression and provided valuable tools for the development of novel cancer treatments. Additionally, these preclinical models are used to predict clinical response to anti‐cancer agents. In this review, we discuss PDTX and PDTO model systems and compare their promises and challenges in cancer research. [Figure: Schematic representation of patient‐derived tumour xenografts and organoids PDTXs preserve tumour heterogeneity and tumour–stroma interactions. PDTOs grow in a provided basement membrane extract and can be established from epithelial cancer cells as well as normal epithelial tissue. Both models allow for several translational applications that contribute to development of therapeutic cancer treatments. Part of this figure was adapted from Sachs and Clevers (2014).] PDTX models To understand cancer biology and its translation into effective treatments, human preclinical models capturing the heterogeneity of cancer are fundamental. Although with low efficiency, primary tumour tissues can be grown in 2D cultures in vitro, allowing tumour cells capable of adapting to these conditions to expand and form a cell line. The use of in vitro cancer cell lines has provided valuable insights on tumour development and mechanisms of therapeutic actions (Sos et al, 2009; Greshock et al, 2010). However, the main drawback of cancer cell lines is the lack of both phenotypic and genetic heterogeneity found in the original tumours (Sachs & Clevers, 2014; Byrne et al, 2017). To enhance the correlation with human cancers, surgically derived primary clinical tumour samples can be grafted into mice, known as PDTX. In such models, tumour architecture and the relative proportion of cancer cells and stromal cells are maintained to a large extent, which yields better resemblance to the original tumour compared to cancer cell lines (Byrne et al, 2017; Fig 2). Although not all patient‐derived tumours can successfully be engrafted into mice, the success rate of PDTX establishment is increasing due to the establishment of immunocompromised mice (Shultz et al, 2005; Drake et al, 2012). Although the first documented attempt to transplant a human cancer into an animal dates back to 1775, a hallmark study by Helene Toolan showed that it was possible to grow human tumour cells in x‐irradiated mice and rats (Toolan, 1953). Additionally, she demonstrated that proliferation extended considerably when the x‐radiated hosts were treated with the immune system suppressor cortisone (Toolan, 1953). Later, Phillips and Gazet were able to obtain a slightly higher percentage of viable patient‐derived tumour grafts by treating the host mice with anti‐lymphocyte serum. The number of viable grafts increased in particular when combined with thymectomy, demonstrating that a suppressed immune response enhances engraftment efficiency (Phillips & Gazet, 1970). Following these studies, several genetically modified mouse models have been established, which are severely immune deficient, such as the NOD/SCID/IL2Rγnull (NSG) mouse (Shultz et al, 2005). The virtual absence of an immune system in these mice allows for significantly higher engraftment rates (Shultz et al, 2005; Byrne et al, 2017). Together these studies demonstrated that loss of immune system activity improves engraftment and viability of patient‐derived tumour tissue into mice. PDTX models are currently established for a broad variety of cancers, including colorectal (Fichtner et al, 2004; Guenot et al, 2006), pancreatic (Fu et al, 1992; Kim et al, 2009), breast (Beckhove et al, 2003; Bruna et al, 2016), lung (Cutz et al, 2006), skin (Taetle et al, 1987), head and neck (Hennessey et al, 2011), prostate (Wang et al, 2005) and ovarian cancer (George et al, 2017; Fig 3). Although PDTXs recapitulate tumour tissue more closely than cancer cell lines, they are usually generated from a small amount of tumour material. As a consequence, the PDTX derived from it might not capture the full heterogeneity of the original tumour (Kemper et al, 2015). Moreover, Morgan and colleagues recently

Read the complete text